Frank is an experienced clinical pharmacologist with deep expertise in oncology drug development, who is leading the execution of clinical development activities for T-CURX's non-viral CAR-T Therapies. Most recently, Frank was Vice President Medical at Heidelberg Pharma, where he was providing medical strategy and oversight for the preparation and conduct of phase I-II clinical studies using BCMA and CD37 targeted ADCs in multiple myeloma and B-cell Lymphoma, respectively. Prior to this, Frank served as Medical Lead for the Immunocytokines and CAR-T cell program and was the Clinical Pharmacology Lead at SOTIO Biotech AG in Basel, Switzerland. 

He brings more than 20 years of development experience in various therapeutic areas incl. orphan haematology and cancer indications across large pharma and biotech.

He holds a MD from Charité Medical University, Berlin, an MBA from University of Applied Sciences, Neu-Ulm, and is a board-certified Clinical Pharmacologist. 

Frank is member of the medical outreach group of the American Statistical Association Bayesian Scientific Working group and shows unique expertise in Digitalization and AI in Pharma and Biotech.